Navigation Links
Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing

IPSWICH, Mass., Sept. 29 /PRNewswire/ -- Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, and Dr. Kamran Shazand, Project Manager, of the Ontario Institute for Cancer Research (OICR) led a team of scientists who have completed a thorough evaluation of the NEBNext(TM) DNA Sample Prep Reagents for use with OICR's Illumina® Genome Analyzer II. Dr. McPherson said of the evaluation, "We are constantly striving for the best quality sequencing results at a price that does not restrict our throughput needs and NEB's new reagents meet this need well."

(Logo: )

"We are extremely pleased that OICR, as a world leading genome center, has determined that our reagents meet their high standards," stated Dr. Peter Nathan, Director of Global Business Development at New England Biolabs.

NEBNext(TM) DNA Sample Prep Reagent Sets contain enzymes and buffers that are ideally suited for sample preparation for next generation sequencing, and for preparation of expression libraries. Reagents are available for each step of the library construction workflow, including end repair, dA-tailing, adapter ligation and amplification. These sets are highly cost effective and each of the components must pass rigorous quality control and validation, including independent third-party evaluation on the appropriate NGS platform.

About New England Biolabs (NEB)

Established in the mid 1970's, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genome research. NEB continues to expand its product offerings into areas related to PCR, cloning, expression and purification, and is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit (

About Ontario Institute for Cancer Research (OICR)

The Ontario Institute for Cancer Research is a new innovative cancer research centre, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. For more information about OICR, visit (

SOURCE New England Biolabs

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nanocopoeia Licenses New Polymer-Based Biomaterials Platform From the University of Western Ontario
2. Sparking Growth In Ontarios Biopharmaceutical Industry
3. Senate President Therese Murray, Massachusetts Life Sciences Center, and Howard Hughes Medical Institute Join Marine Biological Laboratory (MBL) for Loeb Laboratory Groundbreaking Ceremony
4. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
5. HUYA Bioscience Establishes First-Look Agreement With Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH)
6. SRA International Wins $16 Million Contract from Cancer Prevention and Research Institute of Texas
7. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
8. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
9. Bayer CropScience Announces Investment of $25 Million for Institute Site
10. Korea Institute of Toxicology Implementing Xybion's Pristima™
11. K-States Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year
Post Your Comments:
(Date:10/12/2015)... This report covers the global cell expansion ... applications, end-user markets and geographic segmentation. Forecasts are provided ... cell expansion market generated revenue of roughly $8.5 billion ... $9.7 billion in 2015 and $22.0 billion by 2020, ... from 2015 to 2020. This report provides: ...
(Date:10/12/2015)... Oct. 12, 2015  Patara Pharma, a clinical-stage ... inflammatory diseases and conditions, today announced the closing ... financing. Concurrent with the close of its sale ... Loan and Security Agreement with Silicon Valley Bank ... million. Patara will use the funds from the ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty biopharmaceutical company focused ... safely and chronically be administered as an eye drop, announced today it has been ... Clinic and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, ...
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... 29, 2015 News facts: ... also saving energy , Minimized design shrinks PC ... Active Mode and embedded Fujitsu PalmSecure authentication enable enterprises ... Fujitsu today shows that good things come in small ... to its enterprise desktop and mobile portfolio. Featuring workplace ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
Breaking Biology News(10 mins):